BNP Paribas Exane Downgrades Organon & Co. (OGN) to Neutral Post Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Piper Sandler Upgrades Organon & Co. (OGN) to Neutral, raises PT
April 27, 2026 4:25 PM EDTPiper Sandler analyst David Amsellem upgraded Organon & Co. (NYSE: OGN) from Underweight to Neutral with a price target of $14.00 (from $5.00).
For an analyst ratings summary and ratings history on Organon & Co. click here. For more ratings news on Organon & Co. click here.
Shares of Organon & Co. closed at $11.26 yesterday.
... MoreIncreasing unusual option volume: QGEN OGN SGMT CMPX CAR
April 27, 2026 9:48 AM EDTIncreasing unusual option volume: QGEN OGN SGMT CMPX CAR
... MoreSun Pharma to buy US drugmaker Organon for $11.75 billion in India's largest pharma deal
April 27, 2026 1:19 AM EDTBy Kashish Tandon and Rishika Sadam
April 26 (Reuters) - Sun Pharmaceutical Industries will buy U.S. drugmaker Organon & Co in an all-cash deal valued at about $11.75 billion including debt, for the largest overseas acquisition by an Indian pharmaceutical company.
The move comes as Sun, India's biggest drugmaker by market value, steps up a push into higher-margin specialty medicines with a sharper focus on areas such as dermatology, oncology and obesity to offset declining U.S. sales.
Shifting tariff policies in the United States have squeezed margins for one of India's drugmakers most exposed to the American market, prompting it... More
Sun Pharma To Buy Organon For $14/share Cash
April 26, 2026 8:00 PM EDTSun Pharma To Buy Organon For $14/share Cash
... MoreSun Pharma to acquire Organon for $14 per share in $11.75 billion deal
April 26, 2026 7:51 PM EDTSun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced it will acquire Organon & Co. (NYSE: OGN) for $14.00 per share in cash, valuing the healthcare company at $11.75 billion in enterprise value.
The transaction has received approval from both companies' boards of directors and remains subject to regulatory... More
